tert-butyl 3-fluoro-4-(methylsulfonamido)-5-vinylbenzylcarbamate | 911124-07-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl 3-fluoro-4-(methylsulfonamido)-5-vinylbenzylcarbamate
• 英文别名: (3-fluoro-4-methanesulfonylamino-5-vinylbenzyl)carbamic acid t-butyl ester；(3-Fluoro-4-methanesulfonylamino-5-vinyl-benzyl)-carbamic acid t-butyl ester；tert-butyl N-[[3-ethenyl-5-fluoro-4-(methanesulfonamido)phenyl]methyl]carbamate
• CAS: 911124-07-7
• 化学式: C₁₅H₂₁FN₂O₄S
• 分子量: 344.407
• InChiKey: FBLQAJNGKSTZJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  92.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-fluoro-4-(methylsulfonamido)-5-vinylbenzylcarbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 N-(4-aminomethyl-2-fluoro-6-vinylphenyl)methanesulfonamide
  参考文献：
  名称：

  Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same

  摘要：

  本发明涉及化合物的结构式(I)，其中R3代表C2-C5烯基或C2-C5炔基，其他变量如权利要求书中所定义，其异构体或其药学上可接受的盐作为辣椒素受体（辣椒素受体1; VR1; TRPV1）拮抗剂；以及含有该化合物的药物组合物。本发明提供了一种用于预防或治疗疼痛、关节炎炎症性疾病、尿道膀胱过敏（包括尿失禁）、胃十二指肠溃疡、肠易激综合征、炎症性肠病、神经性/过敏/炎症性皮肤病、银屑病、哮喘、慢性阻塞性肺病、瘙痒或痒疹的药物组合物。

  公开号：

  EP1862454A1
• 作为产物：
  描述：

  tert-butyl 3-fluoro-5-iodo-4-(methylsulfonamido)-benzylcarbamate 、 三丁基乙烯基锡 在 四(三苯基膦)钯 作用下， 以 甲苯 为溶剂， 反应 4.0h， 以69%的产率得到tert-butyl 3-fluoro-4-(methylsulfonamido)-5-vinylbenzylcarbamate
  参考文献：
  名称：

  Synthesis and structural optimization of multiple H-bonding region of diarylalkyl (thio)amides as novel TRPV1 antagonists

  摘要：

  Structural optimization of multiple H-bonding region and structure-activity relationship of diarylalkyl amides/thioamides as novel TRPV1 antagonists are described. In particular, we identified amide 34o and thioamides 35o and 35r, of which antagonistic activities were highly enhanced by an incorporation of cyano or vinyl-substituent to the multiple H-bonding region. They exhibited potent Ca-45(2+) uptake inhibitions in rat DRG neuron with IC(50)s of 25, 32 and 28 nM, respectively. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.10.043

文献信息

• NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：Kim Hee-Doo

  公开号：US20090105258A1

  公开（公告）日：2009-04-23

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salt thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

  本发明涉及一种新型化合物，其异构体或药物可接受的盐作为vanilloid受体（Vanilloid Receptor 1；VR1；TRRPV1）拮抗剂；以及含有该化合物的药物组合物。本发明提供了一种用于预防或治疗疾病，如疼痛，偏头痛，关节痛，神经痛，神经病，神经损伤，皮肤疾病，膀胱过敏，肠易激综合征，大便紧急，呼吸系统疾病，皮肤，眼或黏膜刺激，胃十二指肠溃疡，炎症性疾病，耳病和心脏病的药物组合物。
• Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
  申请人：Amorepacific Corporation

  公开号：US07763657B2

  公开（公告）日：2010-07-27

  This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salt thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, and heart disease.

  本发明涉及新型化合物、其异构体或其药学上可接受的盐作为vanilloid受体（Vanilloid Receptor 1; VR1; TRRPV1）拮抗剂；以及含有该化合物的制药组合物。本发明提供了一种用于预防或治疗疾病的制药组合物，例如疼痛、偏头痛、关节痛、神经痛、神经病、神经损伤、皮肤疾病、膀胱过敏、肠易激综合征、排便紧迫、呼吸道疾病、皮肤、眼睛或黏膜刺激、胃十二指肠溃疡、炎症性疾病、耳病和心脏病。
• WO2006/101318
  申请人：——

  公开号：——

  公开（公告）日：——
• NOVEL COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
  申请人：Amorepacific Corporation

  公开号：EP1861357B1

  公开（公告）日：2013-04-24
• US7763657B2
  申请人：——

  公开号：US7763657B2

  公开（公告）日：2010-07-27